COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

While surgery, chemotherapy and radiation therapy have been the basis of cancer treatment for decades, a new type of treatment could be the next core pillar in oncology. Immunotherapy, which stimulates the body’s own immune system to destroy cancer cells, has already been successful when used to treat some blood cancers, and researchers believe it could someday be effective for people with solid tumors like breast, prostate or colorectal cancer.1 

This type of cellular immunotherapy technology is already in clinical trials for a wide variety of cancers. If it is successful, it could become a broad alternative to chemotherapy, or be used in addition to or even in combination with chemotherapy.

“We are harnessing knowledge from decades of research to improve outcomes for patients,” said Nirav Shah, MD, hematologist/oncologist with the Froedtert & MCW Clinical Cancer Center. “There is amazing potential here for the future of cancer treatment, and a healthier world is closer than ever.”

The Froedtert & MCW Cancer Network is enrolling participants in a Phase II clinical trial for people with metastatic and/or recurrent head and neck cancer. The treatment uses tumor-infiltrating lymphocytes made up of specialized white blood cells — T-cells that are grown from a person’s tumor. T-cells are the body’s mechanism for eliminating abnormal cells, so they are the natural enemy of cancer.

Technicians extract a sample of cells from a patient’s tumor. The cells are expanded and activated in a lab to produce a critical dose of tumor-infiltrating lymphocytes. Then, we reinfuse the patient with their own cancer-fighting cells.

Genetically re-engineered CAR T cells are able to recognize a specific protein on the surface of the cancer cells and destroy them.

 

 

By using a person’s own cells, chimeric antigen receptor (CAR) T-cell therapy, prevents the body from rejecting the cells, and the cells do not attack other tissues. Unlike chemotherapy, where the treatment duration is for a set time, CAR T-cell therapy also offers a persistent way of activating the body’s immune system so that it can keep fighting the cancer throughout a person’s lifetime.

Right now, patients throughout the Froedtert & MCW Cancer Network have access to several CAR T-cell therapy options for lymphoma, leukemia and myeloma. These options and others are approved by the Food and Drug Administration for clinical trials for lymphoma and myeloma. Axicabtagene ciloleucel (Yescarta®) is a CAR T-cell therapy for patients with aggressive B-cell lymphomas. Tisagenlecleucel (KYMRIAH®) is another CAR T-cell therapy option approved for adults with aggressive B-cell lymphomas and for pediatric and young adult patients with acute lymphoblastic leukemia.

To learn more about CAR T-cell therapy, visit: froedtert.com/car-t

Add new comment

Leonard
Sommers
on June 2, 2019 - 12:30 pm

Bioelectric code/ cancer/medullary. is there anything on this processes that might show promise on attacking cancer ? next question CART-therapy can this work on medullary cancer ? next question Hypo chamber could this work on cancer ? Medullary cancer ? Loxo what have we learn from trails on attacking Medullary cancer ? when do you think FDA might approved Loxo ? What other products that are coming down the line that is attacking Medullary Cancer ?

Froedtert
& MCW
on June 4, 2019 - 8:23 am

Hi Leonard - Thank you for your interest. Since you have a number of complex questions related to medullary cancer, it might be best if you schedule a second opinion appointment to learn more: https://www.froedtert.com/cancer/second-opinion. We can address treatment options related to your specific situation. Thanks!